Executive Series - Opthea (OPT) CEO & Managing Director, Megan Baldwin


Tom Piotrowski speaks with Opthea (OPT) CEO & Managing Director, Megan Baldwin about the results of its Phase 2 study of its OPT-302 drug aimed at treating the Wet AMD eye disease To view more Executive Series interviews, visit: (VIEW LINK)


CommSec is Australia's leading online broker. CommSec has been committed to providing the best in online trading since 1995. CommSec helps make informed investment decisions with comprehensive market research, free live pricing and powerful...

tom piotrowski opthea ASX: OPT OPT Megan Baldwin


Please sign in to comment on this wire.